GPA33 forms a distinct diagnostic target class to Claudin 18.2 in oesophageal adenocarcinoma enabling the development of a novel GPA33 antibody-based detection platform - PubMed
a day ago
- #Oesophageal adenocarcinoma
- #GPA33
- #Diagnostic target
- GPA33 is identified as a distinct diagnostic target in oesophageal adenocarcinoma (OAC), separate from Claudin 18.2.
- GPA33 shows superior tumor-specific expression compared to Claudin 18.2, which is also found in normal gastric tissue.
- GPA33 and Claudin 18.2 exhibit statistically significant mutually exclusive expression in OAC, suggesting different development pathways.
- A novel monoclonal antibody (RSE-05) targeting GPA33 was developed, with a unique binding interface involving a di-sulphide bridge.
- RSE-05 can be adapted for diagnostic tools, such as ELISA, to measure GPA33 in liquid phase.
- GPA33 captures a patient subset negative for Claudin 18.2, offering new diagnostic and therapeutic opportunities in OAC.